Who
Mitchell Lawrence Jones
Officer
Company insider
Files Form 4 as: Chief Medical Officer, Palisade Bio.
In numbers
- Trades disclosed
- 44
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $220K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 6 Nov 2023
- Last trade
- 6 Oct 2026
- Last filed
- 7 Oct 2026
Companies traded
Activity over time
1 Feb – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Oct 2026filed 7 Oct 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Code M | —2,620,850 | filing |
| 6 Oct 2026filed 7 Oct 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Code F | $1.5M1,031,102 at $1.49 | filing |
| 6 Oct 2026filed 7 Oct 2026 | PALI Palisade Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —2,555,266 at $0.00 | filing |
| 6 Oct 2026filed 7 Oct 2026 | PALI Palisade Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —65,584 at $0.00 | filing |
| 7 Jul 2026filed 8 Jul 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Sold | $107K51,880 at $2.05 | filing |
| 7 Jul 2026filed 8 Jul 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Sold | $106K51,880 at $2.05 | filing |
| 6 Jul 2026filed 8 Jul 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Code M | —131,167 | filing |
| 6 Jul 2026filed 8 Jul 2026 | PALI Palisade Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —131,167 at $0.00 | filing |
| 6 Jul 2026filed 8 Jul 2026 | PALI Palisade Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —131,167 at $0.00 | filing |
| 6 Jul 2026filed 8 Jul 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Code M | —131,167 | filing |
| 12 Feb 2026filed 13 Feb 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Sold | $3,4811,989 at $1.75 | filing |
| 12 Feb 2026filed 13 Feb 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Sold | $3,4811,989 at $1.75 | filing |
| 11 Feb 2026filed 13 Feb 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Code M | —8,000 | filing |
| 11 Feb 2026filed 13 Feb 2026 | PALI Palisade Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —8,000 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | PALI Palisade Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —8,000 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Code M | —8,000 | filing |
| 9 Feb 2026filed 11 Feb 2026 | PALI Palisade Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —787,000 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | PALI Palisade Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —787,000 at $0.00 | filing |
| 6 Oct 2025filed 8 Oct 2025 | PALI Palisade Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —7,665,800 at $0.00 | filing |
| 4 Sep 2025filed 5 Sep 2025 | PALI Palisade Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —289,000 at $0.00 | filing |
News
Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026PALI · manilatimes.net · 20 Oct 2026Palisade Bio (NASDAQ:PALI) Downgraded by Wall Street Zen to "Sell"PALI · themarketsdaily.com · 18 Oct 2026Palisade Bio's (PALI) Buy Rating Reiterated at HC WainwrightPALI · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Mitchell Lawrence Jones; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.